Scientific Presentations and Publications

Presentations

July 2023: Hereditary Angioedema Association National Summit

People Living with Hereditary Angioedema (HAE) Prioritize Attack-Free Status as Target for Therapeutic Efficacy

June 2023: European Academy of Allergy and Clinical Immunology Annual Congress

STAR-0215 Bound to Active Plasma Kallikrein Structure Uncovers a New Binding Mode

June 2023: European Academy of Allergy and Clinical Immunology Annual Congress

Design of a Phase 1b/2 Proof-of-Concept Trial of STAR-0215 as a Long-Acting Preventative Therapy in Patients with Hereditary Angioedema (HAE) Types I or II

June 2023: European Academy of Allergy and Clinical Immunology Annual Congress

Initial Results from a Phase 1a Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema (HAE), in Healthy Adult Subjects Followed for 3 Months

May 2023: 13th C1-Inhibitor Deficiency and Angioedema Workshop

Design of ALPHA-STAR, a Phase 1b/2 proof-of-concept trial of STAR-0215 as a long-acting preventative therapy in patients with hereditary angioedema (HAE) Types I or II

May 2023: 13th C1-Inhibitor Deficiency and Angioedema Workshop

Mechanistic Modeling and Simulations Predict Long-Term HAE Attack Prevention with STAR-0215

February 2023: AAAAI Annual Meeting

Structure of STAR-0215 Bound to Active Plasma Kallikrein Reveals a Novel Mechanism of Enzyme Inhibition

February 2023: AAAAI Annual Meeting

Initial Results from a Phase 1a Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema, in Healthy Adult Subjects Followed for at Least 3 Months

November 2022: ACAAI Annual Scientific Meeting

Modeling and Simulation Predicts Robust HAE Attack Suppression with Every 3 Month Dosing of STAR-0215

July 2022: EAACI Annual Congress

STAR-0215, a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE, Demonstrates Sustained Functional Inhibition in Subcutaneously Dosed Cynomolgus Monkeys